LIU Tao, recognized with Achievement Transformation Award

LIU Tao has adopted a rational drug design strategy to refine the lead compounds obtained by virtual screening over the past seven years, combined with the biological evaluation of molecular-cell-animal level system, and finally selected PY34AC, the candidate drug of CHK1 inhibitor, from more than 100 compounds through multiple cycles. Systematic preclinical studies have shown that PY34AC has significant anti-acute leukemia efficacy and wide treatment window in monotherapy, breaking the idea of CHK1 inhibitors as adjuvant anti-cancer drugs. The candidate drug was approved for clinical trial by the National Medical Products Administration on August 17, 2020.